Related Experiment Video
Updated: Apr 19, 2026

Intrarenal Injection of Escherichia coli in a Rat Model of Pyelonephritis
Published on: July 18, 2017
Incidence of Acute Kidney Injury With the Use of Nafcillin Versus Oxacillin
Alejandro D Perez1, Autumn L Brenner1, Emilia Pieta2
1Department of Pharmacy, University of North Carolina, Medical Center, Chapel Hill, North Carolina, USA.
Background:
Antistaphylococcal penicillins (ASPs) are highly effective against infections caused by methicillin-susceptible Staphylococcus aureus (MSSA). Nafcillin and oxacillin are ASPs with similar spectra of activity, rates of efficacy, pharmacokinetic profiles, and cost. However, there is a growing body of evidence suggesting key distinctions between the safety profiles of nafcillin and oxacillin, including a higher rate of acute kidney injury (AKI) with nafcillin. This retrospective study aims to compare the rate of AKI with nafcillin versus oxacillin at a large academic medical center.
Methods:
A retrospective cohort study was conducted including adult inpatients who were treated with at least six doses of oxacillin or nafcillin. The primary outcome was the incidence of AKI during treatment. Secondary outcomes included change in serum creatinine from baseline, AKI stage, duration of therapy, duration of hospitalization, and in-hospital mortality. Exploratory outcomes included the incidence of moderate hypokalemia, severe hypokalemia, and hepatotoxicity.
Results:
Among 638 patients (171 on nafcillin, 467 on oxacillin), AKI occurred in 33.3% of patients in the nafcillin group compared to 19.5% in the oxacillin group (adjusted risk ratio 1.55, 95% confidence interval 1.16-2.06; p < 0.01). Nafcillin was associated with a greater incidence of AKI at each stage, longer duration of hospitalization, higher in-hospital mortality rate, and increased rates of moderate and severe hypokalemia compared to oxacillin.
Conclusion:
In this study, nafcillin was associated with a significantly higher incidence of AKI than oxacillin.
Insights
Nafcillin is linked to a higher risk of acute kidney injury (AKI) compared to oxacillin in patients treated for Staphylococcus aureus infections. This study highlights important safety differences between these antistaphylococcal penicillins.
Area of Science:
- Pharmacology and Nephrology
- Infectious Diseases and Antibiotic Therapy
Background:
- Antistaphylococcal penicillins (ASPs) like nafcillin and oxacillin are crucial for treating methicillin-susceptible Staphylococcus aureus (MSSA) infections.
- Despite similar efficacy and pharmacokinetic profiles, emerging evidence suggests differing safety profiles, particularly concerning acute kidney injury (AKI).
Purpose of the Study:
- To compare the incidence of AKI between nafcillin and oxacillin in adult inpatients.
- To evaluate secondary outcomes including serum creatinine changes, AKI severity, and mortality.
Main Methods:
- Retrospective cohort study of 638 adult inpatients receiving at least six doses of nafcillin or oxacillin.
- Primary outcome: incidence of AKI during treatment.
- Secondary outcomes: serum creatinine, AKI stage, duration of therapy/hospitalization, mortality, hypokalemia, and hepatotoxicity.
Main Results:
- AKI occurred in 33.3% of nafcillin patients versus 19.5% of oxacillin patients (adjusted risk ratio 1.55, p < 0.01).
- Nafcillin was associated with higher AKI incidence across all stages, longer hospitalizations, increased mortality, and greater rates of hypokalemia.
- Exploratory outcomes also indicated higher rates of moderate and severe hypokalemia with nafcillin.
Conclusions:
- Nafcillin treatment is associated with a significantly higher incidence of AKI compared to oxacillin.
- These findings underscore critical safety distinctions between nafcillin and oxacillin, informing clinical decision-making for MSSA infections.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Pyelonephritis II: Diagnostic Studies and Management
Acute Pyelonephritis I: Introduction
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury III: Clinical Manifestations

